ImpeDx Diagnostics has secured exclusive rights to develop and market a novel system for rapid antimicrobial susceptibility testing (AST) and for detecting bacteria in blood culture specimens, suitable for use in clinical laboratories and at point-of-care.

Our mission is to reduce the growing rate of antibiotic resistance or antimicrobial resistance (AMR), while saving lives and healthcare costs. By addressing the time consuming element of the two step process (ID & AST) healthcare providers use to treat patients suffering from infections with targeted antibiotics and doses, ImpeDx is responding to an ever-growing need and significant medical problem. Our technology compresses the typical AST processes from days/weeks to hours. Not only will our rapid testing platform improve patient outcomes, but it will also have a major impact on healthcare savings.